Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.
Category: Disaster
WHO Resource: WHO Therapeutics and COVID-19: living guideline
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via ...
FDA Resource: Paxlovid received EUA approval from the FDA
December 22, 2021, the FDA issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years o...
FDA Resource: Molnupiravir received EUA approval from the FDA
The FDA has granted molnupiravir emergency use authorization (EUA) to treat mild to moderate COVID-19 in adults at high risk of severe illness. High risk people include adults aged 65 and over and people with certain medical conditions. The FDA also states that molnupiravir sh...
IDSA Resources: Neurology
SCCM’s COVID-19 Rapid Resource Center now links to pertinent content from the Infectious Diseases Society of America (IDSA) COVID-19 Real-Time Learning Network. These resources are categorized as Neurology
I Cannot Let It Go
From Pediatric Critical Care Medicine . In this Editorial, the authors discuss the article by Vacheron et al. on the epidemiology of ventilatory-associated pneumonia among patients with COVID-19.